RESUMO
·AIM:To investigate the clinical efficacy of Ranibizumab combined with laser photocoagulation in the treatment of proliferative diabetic retinopathy (PDR). ·METHODS: Totally 80 patients (101 eyes) with PDR admitted to our hospital from October 2014 and October 2016 were selected and divided into the observation group and the control group, with 50 eyes and 51 eyes respectively. The patients in the control group (50 eyes) were treated with panretinal photocoagulation (PRP), and the patients in observation group (51 eyes) were treated with ranibizumab on the basis of PRP treatment. Best corrected visual acuity(BCVA) was compared before and after surgery 1, 3, and 6mo. Optical coherence tomography (OCT) was used to examine the central macular thickness ( CMT ) and the area of neovascularization at each timepoints. Then the laser spot number,laser energy and energy density were compared between the two groups and the adverse reactions were recorded. · RESULTS: Postoperative BCVA of the two groups significantly increased, and the BCVA of observation group were significantly higher than that of the control group after surgery 1, 3, 6mo, the difference was statistically significant (P<0. 05). After treatment, the CMT and neovascularization area of the two groups significantly decreased, and those of the observation group were significantly lower than those of the control group after surgery 1, 3, 6mo, the difference was statistically significant (P<0.05). The laser spot number, laser energy and energy density of the observation group were significantly lower than those of the control group, the difference was statistically significant(P<0.05). There were 2 cases (2 eyes) in the observation group and 1 cases (1 eye) in the control group, whose intraocular pressure exceeded 28mmHg, while relieved rapidly after the treatment, and no obvious complications occurred in two groups. ·CONCLUSION:Ranibizumab combined with laser in the treatment of PDR is an effective and safe way to improve BCVA, reduce CMT, and eliminate new blood vessels with less required laser energy.
RESUMO
AIM:To comparatively analyze curative effects of intravitreal injection of Ranibizumab and Conbercept in the treatment of diabetic macular edema.METHODS:Retrospectively analyzed the clinical data of 110 patients (110 eyes) with diabetic macular edema treated in our hospital from January 2015 to January 2016,divided them into two groups according to the different treatment.Of these,treated 55 eyes with ranibizumab intravitreal injections (ranibizumab group) and the other with conbercept intravitreal injections (conbercept group),the injection came once a month for 8 continuous months with a 6-month follow-up.Compared the changes of visual acuity,macular thickness,postoperative comfort,clinical efficacy and complications between the two groups after treatment.RESULTS:There was no significant difference in LogMAR visual acuity between the two groups before treatment (P＞ 0.05).The visual acuity of the patients in the ranibizumab group and conbercept group were significantly improved after 1mo treatment,F were 42.06and 64.02 respectively (P＜ 0.01),but there was no significant difference between the two groups after 1mo treatment (P＞0.05).The visual acuity of the conbercept group was significantly higher than that of the ranibizumab group after 3 and 6mo treatment (P＜0.05).There was no significant difference in macular thickness between the two groups before treatment (P＞0.05),the thickness of the macular fovea in the ranibizumab group and conbercept group was lower than that before treatment,there were statistically significant differences (P＜ 0.01);the decline range of conbercept group were more than those of the ranibizumab group after 3 and 6mo (P＜0.05).Patients comfort of the two groups improved with the passage of time after surgery,and there was no significant difference between the two groups (P＞0.05),there were no significant differences in the total effective rate and complication of the ranibizumab group (87.3％,1.8％) and the conbercept group(85.5％,3.6％) (P＞0.05).CONCLUSION:In the treatment of diabetic macular edema,the early vision of patients with diabetic macular edema increases significantly,and the macular thickness decreases significantly.Conbercept works better and has a longer lasting effect after 3 and 6mo treatment,and conbercept is more economical.